Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
06:21pm, Wednesday, 06'th Mar 2024
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to earnings of $4.65 per share a year ago.
VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biothera
Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
12:16am, Tuesday, 05'th Mar 2024
Zymeworks' stock has increased by 67% since September, driven by developments in the antibody-drug conjugate sector. The company's lead asset, zanidatamab, is being developed for the treatment of firs
Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for
11:06am, Wednesday, 28'th Feb 2024
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Tuesday, 27'th Feb 2024
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Last Call! 7 Small-Cap Stocks Ready to Explode in Value
04:19pm, Tuesday, 20'th Feb 2024
The article lists seven small-cap stocks for those looking for opportunities that promise exponential return potential. From innovative biotech firms to edgy technology providers, small-cap stocks are
7 Small-Cap Stocks With Significant Upside Potential in 2024
10:04am, Thursday, 15'th Feb 2024
Investing in small-cap stocks offers multiple advantages for those looking to diversify their portfolios with potential high-growth opportunities efficiently. Small-cap stocks strike a unique balance
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
06:00am, Wednesday, 14'th Feb 2024
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
3 Top Stocks to Buy This Winter for Sizzling Summer Gains
06:14pm, Wednesday, 31'st Jan 2024
The Bulls are back in charge on Wall Street. Major stock indices like the S&P 500 and Dow have powered to new highs recently, with the tech-heavy Nasdaq poised to follow.
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Wednesday, 31'st Jan 2024
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Inc. (ZYME) Is Up 1.64% in One Week: What You Should Know
01:32pm, Thursday, 11'th Jan 2024
Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Let's find out.
$10K to $100K: Small-Cap Marvels With Massive Upside
02:11am, Monday, 08'th Jan 2024
Unlocking the potential of small-cap stocks often reveals sky-bound potential. The three listed stocks in the article offer substantial growth opportunities.
Small-Cap Sensations: 3 Stocks Predicted for Massive Growth in 2024
06:20am, Tuesday, 26'th Dec 2023
As investors, small-cap stocks offer us the possibility of monumental returns. If you play your cards right, small-caps can deliver gains most blue chips could never match.
From $10k to $100k in 5 years: 3 Small-Cap Stocks to Make a Fortune
02:53pm, Monday, 25'th Dec 2023
In the pulsating realm of small-cap stocks, a select few emerge as trailblazers, poised to revolutionize industries and redefine investment landscapes. Enter the triumphant trio of three under-the-rad
Biotech breakthroughs: Stocks that soared from medical innovations
09:08am, Wednesday, 20'th Dec 2023
On the heels of the devastating COVID-19 pandemic, investor enthusiasm for biotech stocks waned as the Federal Reserve embarked on its aggressive rate-hiking campaign to bring down the red-hot inflati
